279 related articles for article (PubMed ID: 29948641)
1. [
Provost C; Rozenblum-Beddok L; Nataf V; Merabtene F; Prignon A; Talbot JN
Mol Imaging Biol; 2019 Apr; 21(2):297-305. PubMed ID: 29948641
[TBL] [Abstract][Full Text] [Related]
2. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
4. Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.
Corroyer-Dulmont A; Pérès EA; Petit E; Guillamo JS; Varoqueaux N; Roussel S; Toutain J; Divoux D; MacKenzie ET; Delamare J; Ibazizène M; Lecocq M; Jacobs AH; Barré L; Bernaudin M; Valable S
Neuro Oncol; 2013 Jan; 15(1):41-56. PubMed ID: 23115160
[TBL] [Abstract][Full Text] [Related]
5. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?
Rylova SN; Barnucz E; Fani M; Braun F; Werner M; Lassmann S; Maecke HR; Weber WA
J Nucl Med; 2014 Nov; 55(11):1878-84. PubMed ID: 25278514
[TBL] [Abstract][Full Text] [Related]
6. Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
Viel T; Schelhaas S; Wagner S; Wachsmuth L; Schwegmann K; Kuhlmann M; Faber C; Kopka K; Schäfers M; Jacobs AH
PLoS One; 2013; 8(7):e67911. PubMed ID: 23861829
[TBL] [Abstract][Full Text] [Related]
7. Comparison and evaluation of two RGD peptides labelled with
Provost C; Prignon A; Rozenblum-Beddok L; Bruyer Q; Dumont S; Merabtene F; Nataf V; Bouteiller C; Talbot JN
Oncotarget; 2018 Apr; 9(27):19307-19316. PubMed ID: 29721204
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.
Provost C; Prignon A; Cazes A; Combaret V; Delattre O; Janoueix-Lerosey I; Montravers F; Talbot JN
Anticancer Res; 2016 Sep; 36(9):4459-66. PubMed ID: 27630282
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme.
Novy Z; Stepankova J; Hola M; Flasarova D; Popper M; Petrik M
Molecules; 2019 Jul; 24(13):. PubMed ID: 31288488
[TBL] [Abstract][Full Text] [Related]
10. (68)Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human glioblastoma.
Fan D; Zhang X; Zhong L; Liu X; Sun Y; Zhao H; Jia B; Liu Z; Zhu Z; Shi J; Wang F
Bioconjug Chem; 2015 Jun; 26(6):1054-60. PubMed ID: 25853280
[TBL] [Abstract][Full Text] [Related]
11. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Lee DY; Chunta JL; Park SS; Huang J; Martinez AA; Grills IS; Krueger SA; Wilson GD; Marples B
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):978-85. PubMed ID: 23845846
[TBL] [Abstract][Full Text] [Related]
12. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.
Dumont RA; Deininger F; Haubner R; Maecke HR; Weber WA; Fani M
J Nucl Med; 2011 Aug; 52(8):1276-84. PubMed ID: 21764795
[TBL] [Abstract][Full Text] [Related]
13. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
[No Abstract] [Full Text] [Related]
14. PET imaging of
Isal S; Pierson J; Imbert L; Clement A; Collet C; Pinel S; Veran N; Reinhard A; Poussier S; Gauchotte G; Frezier S; Karcher G; Marie PY; Maskali F
EJNMMI Res; 2018 Jun; 8(1):51. PubMed ID: 29904818
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
O'Halloran PJ; Viel T; Murray DW; Wachsmuth L; Schwegmann K; Wagner S; Kopka K; Jarzabek MA; Dicker P; Hermann S; Faber C; Klasen T; Schäfers M; O'Brien D; Prehn JH; Jacobs AH; Byrne AT
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1673-83. PubMed ID: 26975402
[TBL] [Abstract][Full Text] [Related]
16. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
Molina D; Pérez-Beteta J; Martínez-González A; Sepúlveda JM; Peralta S; Gil-Gil MJ; Reynes G; Herrero A; De Las Peñas R; Luque R; Capellades J; Balaña C; Pérez-García VM
PLoS One; 2016; 11(8):e0161484. PubMed ID: 27557121
[TBL] [Abstract][Full Text] [Related]
17. PET imaging with [⁶⁸Ga]NOTA-RGD for prostate cancer: a comparative study with [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluoroethylcholine.
Israel I; Richter D; Stritzker J; van Ooschot M; Donat U; Buck AK; Samnick S
Curr Cancer Drug Targets; 2014; 14(4):371-9. PubMed ID: 24720338
[TBL] [Abstract][Full Text] [Related]
18. Imaging of α
Grönman M; Tarkia M; Kiviniemi T; Halonen P; Kuivanen A; Savunen T; Tolvanen T; Teuho J; Käkelä M; Metsälä O; Pietilä M; Saukko P; Ylä-Herttuala S; Knuuti J; Roivainen A; Saraste A
J Transl Med; 2017 Jun; 15(1):144. PubMed ID: 28629432
[TBL] [Abstract][Full Text] [Related]
19. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft Tumors.
Zhai C; Franssen GM; Petrik M; Laverman P; Summer D; Rangger C; Haubner R; Haas H; Decristoforo C
Mol Imaging Biol; 2016 Oct; 18(5):758-67. PubMed ID: 26905697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
